Literature DB >> 33946142

Pituitary Adenomas: From Diagnosis to Therapeutics.

Samridhi Banskota1, David C Adamson1,2,3.   

Abstract

Pituitary adenomas are tumors that arise in the anterior pituitary gland. They are the third most common cause of central nervous system (CNS) tumors among adults. Most adenomas are benign and exert their effect via excess hormone secretion or mass effect. Clinical presentation of pituitary adenoma varies based on their size and hormone secreted. Here, we review some of the most common types of pituitary adenomas, their clinical presentation, and current diagnostic and therapeutic strategies.

Entities:  

Keywords:  CNS tumor; Cushing’s; acromegaly; pituitary adenoma; prolactinoma; transsphenoidal

Year:  2021        PMID: 33946142     DOI: 10.3390/biomedicines9050494

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  145 in total

Review 1.  Clinical practice. Prolactinoma.

Authors:  Janet A Schlechte
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

Review 2.  Diagnosis and complications of Cushing's syndrome: a consensus statement.

Authors:  G Arnaldi; A Angeli; A B Atkinson; X Bertagna; F Cavagnini; G P Chrousos; G A Fava; J W Findling; R C Gaillard; A B Grossman; B Kola; A Lacroix; T Mancini; F Mantero; J Newell-Price; L K Nieman; N Sonino; M L Vance; A Giustina; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

3.  Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.

Authors:  C Di Somma; A Colao; A Di Sarno; M Klain; M L Landi; G Facciolli; R Pivonello; N Panza; M Salvatore; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

4.  Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.

Authors:  Victoria Delgado; Nienke R Biermasz; Sjoerd W van Thiel; See H Ewe; Nina Ajmone Marsan; Eduard R Holman; Richard A Feelders; Johannes W A Smit; Jeroen J Bax; Alberto M Pereira
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

Review 5.  Unveiling the Role of Prolactin and its Receptor in Male Reproduction.

Authors:  Sanketa Raut; Sharvari Deshpande; Nafisa H Balasinor
Journal:  Horm Metab Res       Date:  2019-03-06       Impact factor: 2.936

Review 6.  Dopamine receptor agonists for treating prolactinomas.

Authors:  Annamaria Colao; Antonella di Sarno; Rosario Pivonello; Carolina di Somma; Gaetano Lombardi
Journal:  Expert Opin Investig Drugs       Date:  2002-06       Impact factor: 6.206

7.  Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.

Authors:  Lei Zhang; Xiaojun Wu; Yong Yan; Jun Qian; Yicheng Lu; Chun Luo
Journal:  Brain Dev       Date:  2014-05-10       Impact factor: 1.961

8.  Late-night salivary cortisol as a screening test for Cushing's syndrome.

Authors:  H Raff; J L Raff; J W Findling
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

9.  Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.

Authors:  A M Mattei; C Ferrari; P Baroldi; V Cavioni; A Paracchi; C Galparoli; C Romano; D Spellecchia; G Gerevini; P G Crosignani
Journal:  J Clin Endocrinol Metab       Date:  1988-01       Impact factor: 5.958

Review 10.  A Consensus Statement on acromegaly therapeutic outcomes.

Authors:  Shlomo Melmed; Marcello D Bronstein; Philippe Chanson; Anne Klibanski; Felipe F Casanueva; John A H Wass; Christian J Strasburger; Anton Luger; David R Clemmons; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2018-09       Impact factor: 43.330

View more
  3 in total

1.  A study on serum pro-neurotensin (PNT), furin, and zinc alpha-2-glycoprotein (ZAG) levels in patients with acromegaly.

Authors:  X Ke; L Duan; F Gong; Y Zhang; K Deng; Y Yao; L Wang; F Feng; B Xing; H Pan; H Zhu
Journal:  J Endocrinol Invest       Date:  2022-06-07       Impact factor: 5.467

Review 2.  Immune Checkpoints: Therapeutic Targets for Pituitary Tumors.

Authors:  Ding Nie; Yimeng Xue; Qiuyue Fang; Jianhua Cheng; Bin Li; Dawei Wang; Chuzhong Li; Songbai Gui; Yazhuo Zhang; Peng Zhao
Journal:  Dis Markers       Date:  2021-08-16       Impact factor: 3.434

3.  Alterations of the Gut Microbiome in Patients With Pituitary Adenoma.

Authors:  Jinxian Hu; Jihu Yang; Lei Chen; Xiangbao Meng; Xiejun Zhang; Weiping Li; Zongyang Li; Guodong Huang
Journal:  Pathol Oncol Res       Date:  2022-08-04       Impact factor: 2.874

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.